Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
Here is the latest financial fact sheet of SYNGENE INTERNATIONAL. For more details, see the SYNGENE INTERNATIONAL quarterly results and SYNGENE INTERNATIONAL share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.4 |
No. of shares | m | 402.02 |
1 Week | % | -2.1 |
1 Month | % | 5.8 |
1 Year | % | 16.7 |
52 week H/L | Rs | 860.2/606.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
SYNGENE INTERNATIONAL EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 700 | 702 | 645 | 700 | 682 | |
Low | Rs | 509 | 202 | 230 | 508 | 512 | |
Sales per share (Unadj.) | Rs | 91.3 | 50.3 | 54.6 | 65.0 | 79.5 | |
Earnings per share (Unadj.) | Rs | 16.6 | 10.3 | 10.1 | 9.9 | 11.6 | |
Diluted earnings per share | Rs | 8.2 | 10.3 | 10.1 | 9.8 | 11.6 | |
Cash flow per share (Unadj.) | Rs | 24.8 | 15.8 | 17.0 | 17.6 | 20.7 | |
Dividends per share (Unadj.) | Rs | 0.50 | 0 | 0 | 1.00 | 1.25 | |
Adj. dividends per share | Rs | 0.25 | 0.00 | 0.00 | 1.00 | 1.25 | |
Avg Dividend yield | % | 0.1 | 0 | 0 | 0.2 | 0.2 | |
Book value per share (Unadj.) | Rs | 97.0 | 53.4 | 68.6 | 80.1 | 88.5 | |
Adj. book value per share | Rs | 48.3 | 53.2 | 68.3 | 79.9 | 88.4 | |
Shares outstanding (eoy) | m | 200.00 | 400.00 | 400.00 | 400.80 | 401.43 | |
Price / Sales ratio | x | 6.6 | 9.0 | 8.0 | 9.3 | 7.5 | |
Avg P/E ratio | x | 36.5 | 43.9 | 43.2 | 61.2 | 51.6 | |
P/CF ratio (eoy) | x | 24.4 | 28.6 | 25.7 | 34.3 | 28.8 | |
Price / Book Value ratio | x | 6.2 | 8.5 | 6.4 | 7.5 | 6.7 | |
Dividend payout | % | 3.0 | 0 | 0 | 10.1 | 10.8 | |
Avg Mkt Cap | Rs m | 120,910 | 180,820 | 174,930 | 242,091 | 239,606 | |
Total wages/salary | Rs m | 4,727 | 5,804 | 6,602 | 7,181 | 8,417 |
SYNGENE INTERNATIONAL INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 18,256 | 20,119 | 21,843 | 26,042 | 31,929 | |
Other income | Rs m | 762 | 961 | 833 | 1,084 | 726 | |
Total revenues | Rs m | 19,018 | 21,080 | 22,676 | 27,126 | 32,655 | |
Gross profit | Rs m | 5,357 | 6,747 | 6,881 | 7,098 | 9,327 | |
Depreciation | Rs m | 1,642 | 2,193 | 2,745 | 3,097 | 3,665 | |
Interest | Rs m | 323 | 346 | 277 | 241 | 452 | |
Profit before tax | Rs m | 4,154 | 5,169 | 4,692 | 4,844 | 5,936 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 838 | 1,048 | 643 | 886 | 1,292 | |
Profit after tax | Rs m | 3,316 | 4,121 | 4,049 | 3,958 | 4,644 | |
Gross profit margin | % | 29.3 | 33.5 | 31.5 | 27.3 | 29.2 | |
Effective tax rate | % | 20.2 | 20.3 | 13.7 | 18.3 | 21.8 | |
Net profit margin | % | 18.2 | 20.5 | 18.5 | 15.2 | 14.5 |
SYNGENE INTERNATIONAL BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 17,641 | 16,126 | 18,067 | 22,059 | 24,253 | |
Current liabilities | Rs m | 11,286 | 15,392 | 11,330 | 12,289 | 11,882 | |
Net working cap to sales | % | 34.8 | 3.6 | 30.8 | 37.5 | 38.7 | |
Current ratio | x | 1.6 | 1.0 | 1.6 | 1.8 | 2.0 | |
Inventory Days | Days | 183 | 165 | 163 | 185 | 151 | |
Debtors Days | Days | 68 | 72 | 79 | 71 | 61 | |
Net fixed assets | Rs m | 18,479 | 24,276 | 29,874 | 32,923 | 33,361 | |
Share capital | Rs m | 2,000 | 4,000 | 4,000 | 4,008 | 4,014 | |
"Free" reserves | Rs m | 17,404 | 17,369 | 23,444 | 28,093 | 31,512 | |
Net worth | Rs m | 19,404 | 21,369 | 27,444 | 32,101 | 35,526 | |
Long term debt | Rs m | 3,466 | 0 | 5,124 | 5,315 | 4,890 | |
Total assets | Rs m | 36,120 | 40,402 | 47,941 | 54,982 | 57,614 | |
Interest coverage | x | 13.9 | 15.9 | 17.9 | 21.1 | 14.1 | |
Debt to equity ratio | x | 0.2 | 0 | 0.2 | 0.2 | 0.1 | |
Sales to assets ratio | x | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | |
Return on assets | % | 10.1 | 11.1 | 9.0 | 7.6 | 8.8 | |
Return on equity | % | 17.1 | 19.3 | 14.8 | 12.3 | 13.1 | |
Return on capital | % | 19.6 | 25.8 | 15.3 | 13.6 | 15.8 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 33.9 | 26.3 | 25.3 | 26.8 | 25.2 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 6,188 | 5,287 | 5,521 | 6,967 | 8,048 | |
Fx inflow | Rs m | 16,413 | 18,476 | 20,215 | 23,253 | 30,712 | |
Fx outflow | Rs m | 6,188 | 5,287 | 5,521 | 6,967 | 8,048 | |
Net fx | Rs m | 10,225 | 13,189 | 14,694 | 16,286 | 22,664 |
SYNGENE INTERNATIONAL CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 6,304 | 6,771 | 7,012 | 5,806 | 8,235 | |
From Investments | Rs m | -6,465 | -4,284 | -6,281 | -6,115 | -6,564 | |
From Financial Activity | Rs m | -724 | -2,255 | 580 | -313 | -3,425 | |
Net Cashflow | Rs m | -875 | 278 | 1,303 | -615 | -1,723 |
Share Holding
Shareholding as on Dec 2023
|
Company Information
|
CHM: Kiran Mazumdar Shaw | COMP SEC: Priyadarshini Mahapatra | YEAR OF INC: 1993 | BSE CODE: 539268 | FV (Rs): 10 | DIV YIELD (%): 0.2 |
Read: SYNGENE INTERNATIONAL 2022-23 Annual Report Analysis
More Business Support Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SUN PHARMA CIPLA
Compare SYNGENE INTERNATIONAL With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SUN PHARMA CIPLA
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.